PK makes many of the same points I have on this board.
That article is fascinatingly well reasoned despite the complexity. But I would suggest that is its flaw as well. Biotech players rarely behave that rationally even in much simpler situations.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.